Bristol Myers Squibb Announces FDA Breakthrough Therapy Designation for Investigational LPA1…
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for BMS-986278, a potential first-in-class, oral,…
Read More...
Read More...